289 participants
OPTIM DASATINIB (Optimized Tyrosine Kinase Inhibitors Monotherapy)
- Study Type:
- INTERVENTIONAL
- Last Updated:
- 2026-07-06
- Start Date:
- 2009-05-31
- Completion:
- 2013-12-31
Conditions
- Chronic Myelogenous Leukemia, BCR/ABL Positive
Interventions
- DRUG
No Results Yet